HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

naptumomab estafenatox

an immunotoxin with a distinct mechanism of action and consists of a recombinant fusion protein developed from ABR-214936,6 consisting of a mutated variant of the superantigen (SAg) SEA/E-1207 linked to a fragment antigen binding (Fab) moiety of a monoclonal antibody recognizing the tumor-associated oncofetal trophoblast glycoprotein antigen 5T4; for treatment of patients with advanced non-small-cell lung cancer
Also Known As:
ABR-217620
Networked: 5 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Hedlund, Gunnar: 5 articles (02/2015 - 09/2009)
2. Forsberg, Göran: 4 articles (02/2014 - 09/2009)
3. Sundstedt, Anette: 2 articles (02/2015 - 01/2013)
4. Hawkins, Robert: 2 articles (02/2014 - 09/2009)
5. Burt, Deborah J: 1 article (02/2015)
6. Elkord, Eyad: 1 article (02/2015)
7. Hawkins, Robert E: 1 article (02/2015)
8. Nordle, Örjan: 1 article (02/2015)
9. Eisen, Tim: 1 article (02/2014)
10. Rödström, Karin: 1 article (01/2013)

Related Diseases

1. Neoplasms (Cancer)
2. Renal Cell Carcinoma (Grawitz Tumor)
3. Pancreatic Neoplasms (Pancreatic Cancer)
4. Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
5. Carcinoma (Carcinomatosis)

Related Drugs and Biologics

1. naptumomab estafenatox
2. docetaxel (Taxotere)
3. Antigens
4. T-Cell Antigen Receptors (T-Cell Receptor)
5. Immunotoxins (Immunotoxin)